Home
Resources
Publications
Lithium Carbonate in the Treatment of Graves' Disease With ATD-Induced Hepatic Injury or Leukopenia

Lithium Carbonate in the Treatment of Graves' Disease With ATD-Induced Hepatic Injury or Leukopenia

Rendong Zheng, Kemian Liu, Kun Chen, Wen Cao, Lin Cao, Huifeng Zhang, Hongping Sun, Chao Liu

Int J Endocrinol. 2015;2015:694023.

PMID: 26576153

Abstract:

Objective. GD with ATD-induced hepatic injury or leukopenia occurs frequently in clinical practice. The purpose of the present study was to observe the clinical effect of lithium carbonate on hyperthyroidism in patients with GD with hepatic injury or leukopenia. Methods. Fifty-one patients with GD with hepatic injury or leukopenia participated in the study. All patients were treated with lithium carbonate, in addition to hepatoprotective drugs or drugs that increase white blood cell count. Thyroid function, liver function, and white blood cells were measured. Clinical outcomes were observed after a 1-year follow-up. Results. After treatment for 36 weeks, symptoms of hyperthyroidism and the level of thyroid hormones were improved and liver function, and white blood cells returned to a normal level. Twelve patients (23.5%) obtained clinical remission, 6 patients (11.8%) relapsed after withdrawal, 25 patients (49.0%) received radioiodine therapy, and 8 patients (15.7%) underwent surgical procedures after lithium carbonate treatment. Conclusion. Lithium carbonate has effects on the treatment of mild-to-moderate hyperthyroidism caused by GD, and it is particularly suitable for patients with ATD-induced hepatic injury or leukopenia.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP554132-A	Lithium carbonate		554-13-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: